Prothena Corporation (NASDAQ:PRTA)

CAPS Rating: 2 out of 5

PRTA News and Commentary

Caps

How do you think PRTA will perform against the market?

Add Stock to CAPS Watchlist

All Players

31 Outperform
7 Underperform
 

All-Star Players

11 Outperform
4 Underperform
 

Wall Street

2 Outperform
0 Underperform
 

Top PRTA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.80)
Submitted December 06, 2014

Prothena doesn't seem to have impressed the street much with their recent announcement of positive interim data from the phase I/II trial of NEOD001 anti-amyloid mAb for amyloid light chain (AL) amyloidosis. The company reported a 50% cardiac… More

zzlangerhans (99.80)
Submitted October 22, 2013

Prothena has a healthy market cap of 450M despite a very immature pipeline and a questionable therapeutic platform. The company purports to treat amyloidosis and Parkinson's disease with monoclonal antibodies against abnormally folded proteins, but… More

PRTA VS S&P 500 (SPY)

PRTA Summary

Recent Community Commentary

Read the most recent pitches from players about PRTA.

Recs

0
Member Avatar nakrak (< 20) Submitted: 4/7/2015 2:27:34 PM : Outperform Start Price: $38.12 PRTA Score: +26.75

Good pipeline in addition to present outlook of Parkinsons Diseqse

Recs

3
Member Avatar zzlangerhans (99.80) Submitted: 12/5/2014 8:15:44 PM : Outperform Start Price: $21.85 PRTA Score: +132.89

Prothena doesn't seem to have impressed the street much with their recent announcement of positive interim data from the phase I/II trial of NEOD001 anti-amyloid mAb for amyloid light chain (AL) amyloidosis. The company reported a 50% cardiac response rate and a 43% best renal response rate in the single arm trial, which they claim compares favorably with empiric data from other therapies. Prothena has already initiated the VITAL phase III registrational trial of NEOD001 in AL amyloidosis based on this positive data. Despite this seemingly positive development, Prothena's share price seems to be falling back towards the recent low of 17.5. Perhaps the street hasn't been sensitized to the commercial potential of treatments for amyloidosis, much in the way that NASH was ignored until Intercept's positive data at the beginning of the year. I would not that Prothena enjoys a strong cash position, over 300M, thanks to a large dilutive financing in June. Two other mAb therapeutics are in early clinical development. Prothena doesn't seem to have inspired much of a following in the sector so far, but it could be a nice sleeper pick for 2015.

Leaderboard

Find the members with the highest scoring picks in PRTA.

Score Leader

TrackWedbush

TrackWedbush (84.65) Score: +329.04

The Score Leader is the player with the highest score across all their picks in PRTA.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
maven12 85.91 6/19/2013 Outperform 5Y $13.10 +316.65% +46.78% +269.88 0 Comment
foggs1 71.35 12/8/2014 Outperform 5Y $19.98 +173.22% +16.96% +156.27 0 Comment
tarik500 71.58 7/15/2014 Outperform 5Y $19.79 +175.85% +23.07% +152.78 0 Comment
efarev 97.45 1/12/2015 Outperform 5Y $21.02 +159.71% +19.44% +140.26 0 Comment
odocoileus < 20 12/22/2014 Outperform 5Y $21.62 +152.50% +17.39% +135.10 0 Comment
zzlangerhans 99.80 12/4/2014 Outperform 1Y $21.85 +149.84% +16.95% +132.89 3 Comments
gunda7907 < 20 5/22/2014 Outperform 5Y $20.99 +160.08% +28.30% +131.78 0 Comment
BlueLens 51.10 3/9/2015 Outperform 3Y $26.08 +109.32% +16.83% +92.48 0 Comment
notsorandomwalk 49.96 11/4/2013 Outperform 5Y $24.60 +121.91% +37.43% +84.48 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. zojo360 81.15 2/24/2015 2/19/2016 Outperform 1Y $28.13 +94.06% +14.96% +79.10 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 84.81 3/20/2015 Outperform 3W $38.66 +41.21% +15.35% +25.85 0 Comment
TrackWedbush 84.65 6/27/2013 Outperform NS $11.38 +379.70% +50.66% +329.04 0 Comment